Lower GI 2017

ACCORD 12/0405-Prodige-Trial

Inclusion criteria: cT3-4 Nx, ≤ 80 years , PS 0-1

Adjuvant treatment not specified

T M E

RT 45* Gy (@1.8Gy) + Capecitabine 1600 mg/m 2 /d 5d/w

R

Adjuvant treatment not specified

RT 50* Gy (@ 2.0 Gy) + Capecitabine 1600 mg/m 2 /d 5d/w Oxaliplatin 50 mg/m 2 weekly

T M E

(*15% increase in BED)

Primary endpoint: pCR (11% to 20%), 590 pts required